{"name":"Dutch Childhood Oncology Group","slug":"dutch-childhood-oncology-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan","genericName":"Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan","slug":"etoposide-thioguanine-cyclophosphamide-busulfan-melphalan","indication":"Conditioning regimen for hematopoietic stem cell transplantation in pediatric acute leukemia","status":"phase_3"}]}],"pipeline":[{"name":"Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan","genericName":"Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan","slug":"etoposide-thioguanine-cyclophosphamide-busulfan-melphalan","phase":"phase_3","mechanism":"This is a multi-drug chemotherapy regimen that kills cancer cells through multiple mechanisms including DNA alkylation, purine antagonism, and topoisomerase II inhibition.","indications":["Conditioning regimen for hematopoietic stem cell transplantation in pediatric acute leukemia","Pediatric hematologic malignancies requiring myeloablative therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxObGRWM2FtRTIta3Z0NGJnckN6X1lWVkNReFBQaTVDel9DQWpta2w4UW9mU1ZZZ0xreVZLajFfTEhraEhfVk11a05sdTZIUXdOOU8zY1lDN20tYWJtLUxsdnZSZG95dDR4bHdpQ0lHNENrcUVWWjFDQ1ZvQ0RHanhnbGxZd0NrQ18xWmhHM3BLZEg?oc=5","date":"2026-02-02","type":"regulatory","source":"The Pharma Letter","summary":"FDA slaps CRL on Pharming’s sNDA for Joenja - The Pharma Letter","headline":"FDA slaps CRL on Pharming’s sNDA for Joenja","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNZVR6bGtzQlI3cnBQR0FjVkVQZHE2YlJCblFxbzhDX211YktqYmpOcjM5bllaTHV1b2xTelUwMExKenBoQzJ5WFNyZXZwdFdQcF80WGF3WTdueHRacHZKWVdsX2JuSkQ3TUJYZUV0QjU3T1VHOEJ3Z0VBMGx5dHJ4TlludldFaUlNWnpUbGRmRVQ4NGdQc2dULWxQeDZJb3l3LXUtUnBYWkNzdjhJQzlWN29reVVDU0FWelV3UHVJdUM3XzQ5QmgwUmZGUUZMRXFSNm0tdVFB?oc=5","date":"2025-11-18","type":"regulatory","source":"Journal of Hematology Oncology Pharmacy","summary":"Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents - Journal of Hematology Oncology Pharmacy","headline":"Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQU2MwRFpfdW91Wms2bDZoaHlBbWMzY3lteXNnemVkTDY4dTUxbWdYWmxfLXB5MGhNMTRXOFhsUEU3dXFEWkNCekZxS2ItdDZMWVAzN3BtMmFYQWRQSURlWEJ1czY0dzVwTWVvamdGZE1TclNJdXF6Smhwc241ZFlDRnFocmpaTl9zX2JOMFJNSWo0VS1OUzIzSWN2MUc?oc=5","date":"2025-10-07","type":"pipeline","source":"Holland & Knight","summary":"Holland & Knight Health Dose: October 7, 2025 - Holland & Knight","headline":"Holland & Knight Health Dose: October 7, 2025 - Holland & Knight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1EMlVLdFNlMXVlWnJ3XzNPTUwxeVNMNFRXOTdOU3Q1ZkFaYlZfemRnb1kzS2gyODREVVA5S0dQdnRGMGxpYS13MXFmaVowdTBFRXB2MEwza3U?oc=5","date":"2023-10-11","type":"pipeline","source":"ASCO Publications","summary":"Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL | Journal of Clinical Oncology - ASCO Publications","headline":"Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL | Journal of Clinical Oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQZ1lmRkxnUXNRRW1ab1JJWEc3U1hJWEVVRmhHX1NIem1DTWozUnFuM1otUFN4SUxfcnVlQVg1UWlmZUh2ZkFtTVVnWGRxZ3VHSGJhb1FGMC1pMVR5cXNEWi1YVUw3c19PWS1YU0hQMFlSR25Rbk5GRHBJTHJrdUJCOXl6R2I1aWFKUEwwOXdYSVlBYkl3N05KSTJ3VFZ3eXpWV0tOd3RPdGJiRmpwdGRyNw?oc=5","date":"2022-10-24","type":"pipeline","source":"Renal and Urology News","summary":"CKD, Albuminuria Risk Factors Identified in Childhood Cancer Survivors - Renal and Urology News","headline":"CKD, Albuminuria Risk Factors Identified in Childhood Cancer Survivors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxQRVNIZnFWc3FRdlpaVTkzQTZwTjRDQlEwOVdTUHMzam9TWGQ3WlpUQXBkNzhYc2w5NUNOaDBXWWt3TzREVGRGVmVMYWtuYnNYT1BPTEN0cEw4cExoUnNsWFJYaENxeVBvcnZDQXZLRnEtLWpqcnNhT0lXTFVSaHNLT1cwN3BSTDRmUFFhUzg0anRBVVdjSFFmZEdxR2VBMG96T3c2V1ZSQ2hJOTFBZ2JZOHdVZEhJUW9oYzJtb1ppZjE3UlZCWHVoN0lsN2phSkJDOTBQeWNiU1VlaFlOU0FKV1V2M3QtZVhXdi0xRkR4TldfRllnc0RkSmx5UjZjM014ejZ5aW03SDJGdWNYRDNfU3FsYmF2aU1EZkZlN1pjOERzYS1Qc01DLVlaV3Y0c01CcHdybHdYVTNYaUs0WnpyMkw5Zm9PM1BHQ0pEVGRLUmhtUEstWDQ3Z0VYQQ?oc=5","date":"2021-06-30","type":"regulatory","source":"PR Newswire","summary":"Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma - PR News","headline":"Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for t","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQWE5yM2FabTFlRmxEbVdhSTJfRTZRVTJ0S1hvczZzYTY0M1o0aXFrMGpkbXFSVnBHTUFZV1ZDOG1aVVFLNFFVM1NQdzlIWEU3V3B4anBNSFBTYkQ3eU1ZLXJYSHUwdnlFeHpWa255bzJmVEdJemd2b0ZfT2tucy10NGpBV09tTHlNWVpRQw?oc=5","date":"2021-02-16","type":"pipeline","source":"Frontiers","summary":"Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients - Frontiers","headline":"Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxONUZjZzhQODhvdlh6aWV3WUJwZTBmQ3ZQZUFITEdERzZudS1PQW12RWxOdFlHYmMwOUNqYnc5MmEyVlIzUEZya0VqSHIzTC1SOG5iZTJvSi1BS2k2VjM2V1NJeHRUOGlXbV9Ld2JHLTBsajhUVEhvR3ViNEF2ZVppb2JvWnh0OGk0bjk5MmlOVkVHdmo4WEpIaVJxXzIzZEd0Y09vRHVBcURyb2N5dENhb1ZqWHdHQlRCN0VtQUh1RQ?oc=5","date":"2020-01-30","type":"regulatory","source":"Hematology Advisor","summary":"Therapeutic Drug Monitoring of Asparaginase in Acute Lymphoblastic Leukemia - Hematology Advisor","headline":"Therapeutic Drug Monitoring of Asparaginase in Acute Lymphoblastic Leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1OTEU5QjNBYVVwNXMxaDZIYWZXdWlXUjhSb0Y5OXlwa2JXeko4dU10dTBlM2MzdG1YVUtSdTFYN3NaYTFMa2ZETTMxUWphNG15UFNsQVhhcDVPVFRGTFE4?oc=5","date":"2018-01-12","type":"pipeline","source":"Nature","summary":"High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia - Nature","headline":"High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNUGNxQWFwZXc4bTRVRkNYUUJQNi03WHN4OXZWS1BuVWRUWkN6OUIyaC1XOGIybVRISkFMOFRyb2VkN3FmS0tqejk0SFJrVzRBYWtEWVBGaGpHbGNyQ0NlSGpQODBrZUpSUkIwc21fWURFLVdDdXpTUVhPbHBaMkRzMVB4ME9lVFVxSEhjWXBBUG9oa2wwVmtZUWlEOGxuVjRoTjRqc0dycU82R1hLYS15OUtJb1JCby1SZTRYYjlJblBKYXVybzhZNXAtblM0YjdMQ3hwNER1MmVkVHA5NVNn?oc=5","date":"2016-04-07","type":"pipeline","source":"Oncology Nurse Advisor","summary":"Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults - Oncology Nurse Advisor","headline":"Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxPWXctWDlmUGMtMHhTcXh0WEhnSTl1Tk91LUVjLVhDbkVuZjVXZ2NVbDFqbzg0UVVsUUIyanVRTGNKRVN6WFFTVEVNbGdJbDFpQXc1SWtfNFNybHhERTVQbDRzc045T2VJSjJxWXdFSVZSTEJ1OE9wMHhoUWVPTTdseDV0Z3V1R19aRFJ2LXNwN0R6dnZNMkJrTURhZWM0Q0VtSF9EdlhuY1l5SUlpckpVUlpVclkyOG40OGxVMmp5bm9fczhBcDJfcGNHU1FycXR0MldUR2V5WkMyTmhEblFhU3l0VS1rdUNBRU9QWWRZSk9qYVkwNGhOVkNpNUM5a21R?oc=5","date":"2015-05-04","type":"pipeline","source":"St. Jude Children's Research Hospital","summary":"Discovery could help reverse glucocorticoid resistance in some young leukemia patients - St. Jude Children's Research Hospital","headline":"Discovery could help reverse glucocorticoid resistance in some young leukemia patients - St. Jude Children's Research Ho","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxORWEzRTd4VG5lLVBibnphSXpZbnNfdC1Bb3U4WXRVQW5yZjdsS2VpWGRfeHFRSFk1a3lZWTVhNWllc1BDYi1CWVdzQzhrdi1nYWNiUHhrdnVKcGRZMFBIeHg0Rkpta0QwQmI5Z2RrUDR2X0laUkxVNVl4NW1xUE1oRkI2RWUwdw?oc=5","date":"2009-01-09","type":"trial","source":"The Lancet","summary":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study - The Lancet","headline":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}